Guggenheim downgraded HilleVax to Neutral from Buy and removed the firm’s price target following the “extremely disappointing results” from the event-driven Phase 2 pediatric study. With just a 5% VE separation and the pediatric opportunity being core to the firm’s thesis, the firm expects shares to trade at or below cash for the foreseeable future, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLVX: